23andme Holding Intrinsic Value Calculation – Rockefeller Capital Management L.P. Increases Stake in 23ANDME HOLDING Co.
February 3, 2023
Trending News 🌥️
23andme Holding Intrinsic Value Calculation – Rockefeller Capital Management L.P. recently announced an increase in their stake in 23ANDME HOLDING ($NASDAQ:ME) Co. This is a major development in the company’s history, as it signals a renewed interest in the potential of the business. The company’s mission is to help people understand their genetic makeup and make informed decisions about their health and lifestyle. The investment from Rockefeller Capital Management L.P. is a major milestone for 23ANDME HOLDING Co., as it signals a renewed interest in the potential of the company. The investment will provide the company with resources to further develop their products and services, as well as to continue to expand their reach in the industry.
This investment is likely to have a significant impact on the company’s future growth and success. It is clear that 23ANDME HOLDING Co. is making strides in the industry and is well-positioned to continue to grow and succeed in the coming years. With the additional investment from Rockefeller Capital Management L.P., the company is sure to be able to expand its offerings and reach a wider audience. This is an exciting development for the company, and one that is sure to lead to success in the future.
Stock Price
Rockefeller Capital Management L.P. recently increased its stake in 23ANDME HOLDING Co, a company focused on providing individuals with direct access to their personal genetic information. At the time of writing, media coverage of this move has been mostly positive. On Thursday, 23ANDME HOLDING stock opened at $2.6 and closed at $2.8, a rise of 7.4% from its previous closing price of $2.6. This increase follows the announcement of increased support from Rockefeller Capital Management L.P., which is expected to further boost the company’s long-term prospects. The move by Rockefeller Capital Management L.P. signals their belief in 23ANDME HOLDING’s potential as a leader in the field of personal genetic data. This sentiment is also shared by other investors, who have been boosting the stock price in recent weeks. The success of 23ANDME HOLDING Co. is due in part to their unique approach to providing customers with direct access to their personal genetic information. By allowing customers to access their data without needing to go through a third party, they have been able to build trust and loyalty with their customers.
Additionally, 23ANDME HOLDING Co. has invested heavily in research and development, leading to a wide range of products and services designed to make understanding one’s genetic information easier than ever before. This has also allowed them to stay ahead of the competition and remain competitive in an increasingly crowded market. With its focus on providing direct access to personal genetic information, it is likely that the company will continue to experience growth in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 23andme Holding. More…
| Total Revenues | Net Income | Net Margin |
| 297.62 | -314.54 | -91.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 23andme Holding. More…
| Operations | Investing | Financing |
| -205.78 | -103.97 | 18.48 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 23andme Holding. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.04k | 221.41 | 1.8 |
Key Ratios Snapshot
Some of the financial key ratios for 23andme Holding are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -93.5% |
| FCF Margin | ROE | ROA |
| -72.4% | -24.2% | -19.4% |
Analysis – 23andme Holding Intrinsic Value Calculation
GoodWhale has conducted an analysis of 23ANDME HOLDING‘s wellbeing and determined that its fair value is around $7.1. This figure has been calculated using GoodWhale’s proprietary Valuation Line. This means that the current trading price of 23ANDME HOLDING stock, $2.8, is massively undervalued by 60.7%. This could present a great opportunity for investors looking to buy a stake in 23ANDME HOLDING. With the stock trading so far below its fair value, investors could potentially benefit from a significant return on their investment once the stock returns to its fair value level. Additionally, with such an undervalued stock, 23ANDME HOLDING may also be an attractive target for potential acquirers. Companies may be keen to take advantage of the current pricing and snap up a bargain. This could also be beneficial for investors, as the stock price could be driven up if the possibility of acquisition is seen as likely. For those considering investing in 23ANDME HOLDING stock, it is important to keep in mind that there are always risks associated with any investment. Careful consideration should be given to assess the potential risks before making a decision. More…
Peers
The company offers a range of tests, including those for ancestry, health, and wellness. Its competitors include IQVIA Holdings Inc, Illumina Inc, and Avricore Health Inc.
– IQVIA Holdings Inc ($NYSE:IQV)
In 2022, IQVIA Holdings Inc had a market capitalization of $40.44 billion and a return on equity of 21.52%. The company provides data, information and technology solutions that help customers drive healthcare insights and solutions.
– Illumina Inc ($NASDAQ:ILMN)
Illumina Inc has a market cap of 34.93B as of 2022, a Return on Equity of -29.49%. The company is a provider of sequencing and array-based solutions for genetic analysis. The company’s products are used by researchers, physicians, patients and parents to make better decisions about health, agriculture, pharmaceuticals, research and many other areas.
– Avricore Health Inc ($TSXV:AVCR)
Avricore Health Inc is a Canadian biotechnology company that develops and commercializes products for the early detection and prevention of chronic disease. The company has a market cap of 25.4 million as of 2022 and a return on equity of -46.21%. Avricore’s products are based on its proprietary technology, which uses a combination of blood tests and genetic tests to identify individuals at risk for developing chronic diseases such as heart disease, stroke, and cancer.
Summary
Rockefeller Capital Management L.P. recently increased its stake in 23ANDME HOLDING Co., indicating a positive sentiment from the investment firm. Media coverage on the event has been mostly favorable and the stock price of the company has seen an increase since the news was made public. This suggests that investors have faith in 23ANDME HOLDING’s potential, as they look to take advantage of the potential upside of the stock. Overall, investors appear confident in 23ANDME HOLDING’s future prospects, which is likely to have a positive impact on the stock.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
